Vasculan Sales Forecast, and Market Size Analysis – 2034
Description
Key Factors Driving Vasculan Growth
1. Rising Prevalence of Chronic Venous Insufficiency (CVI)
CVI includes varicose veins, edema, and venous ulcers, affecting a significant adult population globally.
The condition is chronic and progressive, requiring long-term management rather than acute therapy.
Vasculera is specifically indicated for CVI-related symptoms and vascular inflammation.
Growth implication: Expanding patient pool + chronic use supports steady prescription volume growth.
2. Unique Positioning as a “Medical Food” (Regulatory Advantage)
Vasculera is classified as a medical food, not a conventional drug, designed for disease-specific nutritional management.
This allows:
Facilitates physician-driven prescribing in specialty vascular clinics
3. Mechanism Targeting Endothelial Dysfunction & Inflammation
Contains diosmiplex (a purified flavonoid fraction), which helps:
Drives adoption in patients inadequately controlled with compression therapy alone
4. Favorable Safety Profile Supporting Long-Term Use
Reported side effects are generally mild (e.g., headache, GI upset).
No major systemic safety concerns compared to anticoagulants or invasive procedures
5. Increasing Shift Toward Conservative / Non-Surgical Management
Clinical practice increasingly emphasizes:
Positioned as a first-line adjunct, expanding utilization before invasive treatments
Vasculan Recent Developments
In March 2026, Alebund Pharmaceuticals announced that it entered into licensing and equity agreements (the ""Agreements"") with R1 Therapeutics, Inc. (""R1""). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M. R1 is backed by major global kidney care providers, DaVita, one of the largest kidney care providers globally, and U.S. Renal Care, the largest privately held dialysis provider in the United States and a syndicate of leading global venture capital investors.
“Vasculan Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Vasculan for potential indication like Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma in the 7MM. A detailed picture of Vasculan’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Vasculan for potential indications. The Vasculan market report provides insights about Vasculan’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Vasculan performance, future market assessments inclusive of the Vasculan market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Vasculan sales forecasts, along with factors driving its market.
Vasculan Drug Summary
Vasculan is a vasoactive drug containing calcium dobesilate, primarily used in the management of chronic venous insufficiency, diabetic retinopathy, and other microvascular disorders. It exerts its therapeutic effects by reducing capillary permeability, improving endothelial function, and decreasing blood viscosity, thereby enhancing microcirculation and reducing edema. Vasculan also exhibits antioxidant properties and helps stabilize the basement membrane of capillaries, which is particularly beneficial in preventing progression of diabetic microangiopathy. Administered orally, it is generally well tolerated, with mild gastrointestinal disturbances being the most commonly reported adverse effects, although rare cases of agranulocytosis have been noted, necessitating monitoring in long-term use. The report provides Vasculan’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Vasculan Market Report
The report provides insights into:
A comprehensive product overview including the Vasculan MoA, description, dosage and administration, research and development activities in potential indication like Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma.
Elaborated details on Vasculan regulatory milestones and other development activities have been provided in Vasculan market report.
The report also highlights Vasculan‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
The Vasculan market report also covers the patents information, generic entry and impact on cost cut.
The Vasculan market report contains current and forecasted Vasculan sales for potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Vasculan market report also features the SWOT analysis with analyst views for Vasculan in potential indications.
Methodology
The Vasculan market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Vasculan Analytical Perspective by DelveInsight
In-depth Vasculan Market Assessment
This Vasculan sales market forecast report provides a detailed market assessment of Vasculan for potential indication like Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Vasculan sales data uptil 2034.
Vasculan Clinical Assessment
The Vasculan market report provides the clinical trials information of Vasculan for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Vasculan Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Vasculan Market Potential & Revenue Forecast
Projected market size for the Vasculan and its key indications
Estimated Vasculan sales potential (Vasculan peak sales forecasts)
Vasculan Pricing strategies and reimbursement landscape
Vasculan Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
Vasculan Market positioning compared to existing treatments
Vasculan Strengths & weaknesses relative to competitors
Vasculan Regulatory & Commercial Milestones
Vasculan Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
Vasculan Clinical Differentiation
Vasculan Efficacy & safety advantages over existing drugs
Vasculan Unique selling points
Vasculan Market Report Highlights
In the coming years, the Vasculan market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Vasculan companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Vasculan’s dominance.
Other emerging products for Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma are expected to give tough market competition to Vasculan and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Vasculan in potential indications.
Analyse Vasculan cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Vasculan sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Vasculan in potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of Vasculan? How strong is Vasculan’s clinical and commercial performance?
What is Vasculan’s clinical trial status in each individual indications such as Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Vasculan Manufacturers?
What are the key designations that have been granted to Vasculan for potential indications? How are they going to impact Vasculan’s penetration in various geographies?
What is the current and forecasted Vasculan market scenario for potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Vasculan in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Vasculan for potential indications?
Which are the late-stage emerging therapies under development for the treatment of potential indications?
How cost-effective is Vasculan? What is the duration of therapy and what are the geographical variations in cost per patient?
1. Rising Prevalence of Chronic Venous Insufficiency (CVI)
CVI includes varicose veins, edema, and venous ulcers, affecting a significant adult population globally.
The condition is chronic and progressive, requiring long-term management rather than acute therapy.
Vasculera is specifically indicated for CVI-related symptoms and vascular inflammation.
Growth implication: Expanding patient pool + chronic use supports steady prescription volume growth.
2. Unique Positioning as a “Medical Food” (Regulatory Advantage)
Vasculera is classified as a medical food, not a conventional drug, designed for disease-specific nutritional management.
This allows:
- Lower regulatory barriers vs. biologics/drugs
- Faster commercialization and lifecycle flexibility
Facilitates physician-driven prescribing in specialty vascular clinics
3. Mechanism Targeting Endothelial Dysfunction & Inflammation
Contains diosmiplex (a purified flavonoid fraction), which helps:
- Improve vascular tone
- Reduce capillary permeability and inflammation (documented in flavonoid literature/PubMed studies)
Drives adoption in patients inadequately controlled with compression therapy alone
4. Favorable Safety Profile Supporting Long-Term Use
Reported side effects are generally mild (e.g., headache, GI upset).
No major systemic safety concerns compared to anticoagulants or invasive procedures
5. Increasing Shift Toward Conservative / Non-Surgical Management
Clinical practice increasingly emphasizes:
- Compression therapy + pharmacological adjuncts before surgery
Positioned as a first-line adjunct, expanding utilization before invasive treatments
Vasculan Recent Developments
In March 2026, Alebund Pharmaceuticals announced that it entered into licensing and equity agreements (the ""Agreements"") with R1 Therapeutics, Inc. (""R1""). R1 is a newly launched clinical-stage biotechnology company that recently completed an oversubscribed Series A financing of $77.5M. R1 is backed by major global kidney care providers, DaVita, one of the largest kidney care providers globally, and U.S. Renal Care, the largest privately held dialysis provider in the United States and a syndicate of leading global venture capital investors.
“Vasculan Sales Forecast, and Market Size Analysis – 2034” report provides comprehensive insights of Vasculan for potential indication like Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma in the 7MM. A detailed picture of Vasculan’s existing usage in anticipated entry and performance in potential indications in the 7MM, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan for the study period 2020 –2034 is provided in this report along with a detailed description of the Vasculan for potential indications. The Vasculan market report provides insights about Vasculan’s sales forecast, mechanism of action (MoA), dosage and administration, as well as research and development including regulatory milestones, along with other developmental activities. Further, it also consists of historical and current Vasculan performance, future market assessments inclusive of the Vasculan market forecast analysis for potential indications in the 7MM, SWOT, analysts’ views, comprehensive overview of market competitors, and brief about other emerging therapies in respective indications. It also provides analysis of Vasculan sales forecasts, along with factors driving its market.
Vasculan Drug Summary
Vasculan is a vasoactive drug containing calcium dobesilate, primarily used in the management of chronic venous insufficiency, diabetic retinopathy, and other microvascular disorders. It exerts its therapeutic effects by reducing capillary permeability, improving endothelial function, and decreasing blood viscosity, thereby enhancing microcirculation and reducing edema. Vasculan also exhibits antioxidant properties and helps stabilize the basement membrane of capillaries, which is particularly beneficial in preventing progression of diabetic microangiopathy. Administered orally, it is generally well tolerated, with mild gastrointestinal disturbances being the most commonly reported adverse effects, although rare cases of agranulocytosis have been noted, necessitating monitoring in long-term use. The report provides Vasculan’s sales, growth barriers and drivers, post usage and approvals in multiple indications.
Scope of the Vasculan Market Report
The report provides insights into:
A comprehensive product overview including the Vasculan MoA, description, dosage and administration, research and development activities in potential indication like Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma.
Elaborated details on Vasculan regulatory milestones and other development activities have been provided in Vasculan market report.
The report also highlights Vasculan‘s cost estimates and regional variations, reported and estimated sales performance, research and development activities in potential indications across the United States, Europe, and Japan.
The Vasculan market report also covers the patents information, generic entry and impact on cost cut.
The Vasculan market report contains current and forecasted Vasculan sales for potential indications till 2034.
Comprehensive coverage of the late-stage emerging therapies for respective indications.
The Vasculan market report also features the SWOT analysis with analyst views for Vasculan in potential indications.
Methodology
The Vasculan market report is built using data and information sourced primarily from internal databases, primary and secondary research and in-house analysis by DelveInsight’s team of industry experts. Information and data from the secondary sources have been obtained from various printable and nonprintable sources like search engines, news websites, global regulatory authorities websites, trade journals, white papers, magazines, books, trade associations, industry associations, industry portals and access to available databases.
Vasculan Analytical Perspective by DelveInsight
In-depth Vasculan Market Assessment
This Vasculan sales market forecast report provides a detailed market assessment of Vasculan for potential indication like Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma in the seven major markets, i.e., the United States, EU4 (Germany, France, Italy, and Spain) and the United Kingdom, and Japan. This segment of the report provides current and forecasted Vasculan sales data uptil 2034.
Vasculan Clinical Assessment
The Vasculan market report provides the clinical trials information of Vasculan for potential indications covering trial interventions, trial conditions, trial status, start and completion dates.
Vasculan Competitive Landscape
The report provides Insights on competitors and marketed products within the domain, along with a summary of emerging products and their respective launch dates, posing significant competition in the market.
Vasculan Market Potential & Revenue Forecast
Projected market size for the Vasculan and its key indications
Estimated Vasculan sales potential (Vasculan peak sales forecasts)
Vasculan Pricing strategies and reimbursement landscape
Vasculan Competitive Intelligence
Number of competing drugs in development (pipeline analysis)
Vasculan Market positioning compared to existing treatments
Vasculan Strengths & weaknesses relative to competitors
Vasculan Regulatory & Commercial Milestones
Vasculan Key regulatory approvals & expected launch timelines
Commercial partnerships, licensing deals, and M&A activity
Vasculan Clinical Differentiation
Vasculan Efficacy & safety advantages over existing drugs
Vasculan Unique selling points
Vasculan Market Report Highlights
In the coming years, the Vasculan market scenario is set to change due to strong adoption, increased prescriptions and broader uptake in multiple immunological indications; which would expand the size of the market.
The Vasculan companies are developing therapies that focus on novel approaches to treat/improve the disease condition, assess challenges, and seek opportunities that could influence Vasculan’s dominance.
Other emerging products for Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma are expected to give tough market competition to Vasculan and launch of late-stage emerging therapies in the near future will significantly impact the market.
A detailed description of regulatory milestones, and developmental activities, provide the current development scenario of Vasculan in potential indications.
Analyse Vasculan cost, pricing trends and market positioning to support strategic decision-making in the immunology landscape.
Our in-depth analysis of the forecasted Vasculan sales data uptil 2034 will support the clients in decision-making process regarding their therapeutic portfolio by identifying the overall scenario of Vasculan in potential indications.
Key Questions
What is the class of therapy, route of administration and mechanism of action of Vasculan? How strong is Vasculan’s clinical and commercial performance?
What is Vasculan’s clinical trial status in each individual indications such as Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma and study completion date?
What are the key collaborations, mergers and acquisitions, licensing and other activities related to the Vasculan Manufacturers?
What are the key designations that have been granted to Vasculan for potential indications? How are they going to impact Vasculan’s penetration in various geographies?
What is the current and forecasted Vasculan market scenario for potential indications? What are the key assumptions behind the forecast?
What are the current and forecasted sales of Vasculan in the seven major countries, including the United States, Europe (Germany, France, Italy, Spain) and the United Kingdom, and Japan?
What are the other emerging products available and how are these giving competition to Vasculan for potential indications?
Which are the late-stage emerging therapies under development for the treatment of potential indications?
How cost-effective is Vasculan? What is the duration of therapy and what are the geographical variations in cost per patient?
Table of Contents
30 Pages
- 1. Report Introduction
- 2. Vasculan Overview in potential indication like Asthma, Cardiomyopathies, Cardiovascular disorders, Hepatorenal syndrome, Idiopathic pulmonary fibrosis, Portal hypertension, Solid tumours, and Systemic scleroderma
- 2.1. Product Detail
- 2.2. Vasculan Clinical Development
- 2.2.1. Vasculan Clinical studies
- 2.2.2. Vasculan Clinical trials information
- 2.2.3. Safety and efficacy
- 2.3. Other Developmental Activities
- 2.4. Product Profile
- 3. Vasculan Competitive Landscape (Marketed Therapies)
- 4. Competitive Landscape (Late-stage Emerging Vasculan Therapies)
- 5. Vasculan Market Assessment
- 5.1. Vasculan Market Outlook in potential indications
- 5.2. 7MM Analysis
- 5.2.1. Vasculan Market Size in the 7MM for potential indications
- 5.3. Country-wise Market Analysis
- 5.3.1. Vasculan Market Size in the United States for potential indications
- 5.3.2. Vasculan Market Size in Germany for potential indications
- 5.3.3. Vasculan Market Size in France for potential indications
- 5.3.4. Vasculan Market Size in Italy for potential indications
- 5.3.5. Vasculan Market Size in Spain for potential indications
- 5.3.6. Vasculan Market Size in the United Kingdom for potential indications
- 5.3.7. Vasculan Market Size in Japan for potential indications
- 6. Vasculan SWOT Analysis
- 7. Analysts’ Views
- 8. Appendix
- 8.1. Bibliography
- 8.2. Report Methodology
- 9. DelveInsight Capabilities
- 10. Disclaimer
- 11. About DelveInsight
- 12. Report Purchase Options
Pricing
Currency Rates
Questions or Comments?
Our team has the ability to search within reports to verify it suits your needs. We can also help maximize your budget by finding sections of reports you can purchase.
